SAN DIEGO–(BUSINESS WIRE)—- $REVB #AKI–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative therapies designed to rebalance the body’s inflammatory response, today announced a strategic shift designed to accelerate development of Gemini, its proprietary therapeutic candidate designed to restore the body’s natural inflammatory balance through multiple biological pathways. The strategy includes advancing a streamlined Phase